Literature DB >> 10212897

Use of artemisinin derivatives for the control of malaria.

F Nosten1, T T Hien, N J White.   

Abstract

Since 1994, the combination of mefloquine and artesunate is the standard treatment for uncomplicated Plasmodium falciparum malaria in the population of displaced persons on the Western border of Thailand. As a result, the fall of mefloquine efficacy was stopped and the incidence of falciparum malaria reduced. This is attributed to the effects of the artemisinin derivatives on transmissibility. Similar trends were observed in Vietnam where artemisinin is widely used. Combination therapies that include an artemisinin derivative could have a major role in the control of malaria and the spread of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10212897

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  10 in total

1.  Transmission-blocking activities of quinine, primaquine, and artesunate.

Authors:  Kesinee Chotivanich; Jetsumon Sattabongkot; Rachanee Udomsangpetch; Sornchai Looareesuwan; Nicholas P J Day; Russell E Coleman; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Resurgent malaria at the millennium: control strategies in crisis.

Authors:  J K Baird
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 3.  Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination.

Authors:  Rashad Abdul-Ghani; John C Beier
Journal:  Parasitol Res       Date:  2014-09-04       Impact factor: 2.289

4.  Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine.

Authors:  A Brockman; R N Price; M van Vugt; D G Heppner; D Walsh; P Sookto; T Wimonwattrawatee; S Looareesuwan; N J White; F Nosten
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.184

5.  Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.

Authors:  Toufigh Gordi; Dinh Xuan Huong; Trinh Ngoc Hai; Nguyen Thi Nieu; Michael Ashton
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria.

Authors:  Sasithon Pukrittayakamee; Kesinee Chotivanich; Arun Chantra; Ralf Clemens; Sornchai Looareesuwan; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

7.  Investigation of Antiparasitic Activity of 10 European Tree Bark Extracts on Toxoplasma gondii and Bioguided Identification of Triterpenes in Alnus glutinosa Barks.

Authors:  Pierre Darme; Jérémy Spalenka; Jane Hubert; Sandie Escotte-Binet; Laurent Debelle; Isabelle Villena; Charlotte Sayagh; Nicolas Borie; Agathe Martinez; Benjamin Bertaux; Laurence Voutquenne-Nazabadioko; Jean-Hugues Renault; Dominique Aubert
Journal:  Antimicrob Agents Chemother       Date:  2021-10-11       Impact factor: 5.191

8.  Trends in malaria morbidity following the introduction of artesunate plus amodiaquine combination in M'lomp village dispensary, south-western Senegal.

Authors:  Sophie Sarrassat; Paul Senghor; Jean Yves Le Hesran
Journal:  Malar J       Date:  2008-10-24       Impact factor: 2.979

Review 9.  New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China.

Authors:  Yi-Xin Liu; Wei Wu; Yue-Jin Liang; Zu-Liang Jie; Hui Wang; Wei Wang; Yi-Xin Huang
Journal:  Molecules       Date:  2014-09-19       Impact factor: 4.411

10.  Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model.

Authors:  Nick Scott; Ricardo Ataide; David P Wilson; Margaret Hellard; Ric N Price; Julie A Simpson; Freya J I Fowkes
Journal:  Malar J       Date:  2018-08-02       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.